The Effect of Bone Marrow Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction: Twelve Months CMR and Long-Term Clinical Results

Daniel Sürder, Robert Manka, Tiziano Moccetti, Viviana Lo Cicero, Maximilian Y. Emmert, Catherine Klersy, Sabrina Soncin, Lucia Turchetto, Marina Radrizzani, Michel Zuber, Stephan Windecker, Aris Moschovitis, Ines Bühler, Sebastian Kozerke, Paul Erne, Thomas F. Lüscher, Roberto Corti

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

RATIONALE:: Intracoronary delivery of autologous bone marrow derived mononuclear cells (BM-MNC) may improve remodeling of the left ventricle (LV) after acute myocardial infarction (AMI). OBJECTIVE:: To demonstrate long-term efficacy of BM-MNC treatment after AMI. METHODS AND RESULTS:: In a multi-center study, we randomized 200 patients with large AMI in a 1:1:1 pattern into an open-labeled control and two BM-MNC treatment groups. In the BM-MNC groups cells were either administered 5-7 days („early') or 3-4 weeks („late') after AMI. Cardiac magnetic resonance imaging (CMR) was performed at baseline and after 12 months. The current analysis investigates the change from baseline to 12 months in global LV ejection fraction (LVEF), LV-volumes, scar size and NT-proBNP values comparing the two treatment groups with control in a linear regression model. Besides the complete case analysis, multiple imputation analysis was performed to address for missing data. Furthermore the long-term clinical event rate was computed.The absolute change in LVEF from baseline to 12 months was -1.9±9.8 % for control (mean±SD), -0.9±10.5 % for the early and -0.7±10.1 % for the late treatment group. The difference between the groups was not significant, both for complete case analysis and multiple imputation analysis.A combined clinical endpoint occurred equally in all groups. Overall 1-year mortality was low (2.25%). CONCLUSIONS:: Among patients with AMI and LV dysfunction, treatment with BM-MNC either 5-7 days or 3-4 weeks after AMI, did not improve LV-function at 12 months, compared to control. The results are limited by an important drop out rate. CLINICAL TRIAL REGISTRATION INFORMATION:: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00355186

Original languageEnglish
JournalCirculation Research
DOIs
Publication statusAccepted/In press - Jun 10 2016

Fingerprint

Bone Marrow
Myocardial Infarction
Magnetic Resonance Imaging
Heart Ventricles
Linear Models
Therapeutics
Ventricular Remodeling
Cicatrix
Clinical Trials
Control Groups
Mortality

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

The Effect of Bone Marrow Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction : Twelve Months CMR and Long-Term Clinical Results. / Sürder, Daniel; Manka, Robert; Moccetti, Tiziano; Lo Cicero, Viviana; Emmert, Maximilian Y.; Klersy, Catherine; Soncin, Sabrina; Turchetto, Lucia; Radrizzani, Marina; Zuber, Michel; Windecker, Stephan; Moschovitis, Aris; Bühler, Ines; Kozerke, Sebastian; Erne, Paul; Lüscher, Thomas F.; Corti, Roberto.

In: Circulation Research, 10.06.2016.

Research output: Contribution to journalArticle

Sürder, D, Manka, R, Moccetti, T, Lo Cicero, V, Emmert, MY, Klersy, C, Soncin, S, Turchetto, L, Radrizzani, M, Zuber, M, Windecker, S, Moschovitis, A, Bühler, I, Kozerke, S, Erne, P, Lüscher, TF & Corti, R 2016, 'The Effect of Bone Marrow Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction: Twelve Months CMR and Long-Term Clinical Results', Circulation Research. https://doi.org/10.1161/CIRCRESAHA.116.308639
Sürder, Daniel ; Manka, Robert ; Moccetti, Tiziano ; Lo Cicero, Viviana ; Emmert, Maximilian Y. ; Klersy, Catherine ; Soncin, Sabrina ; Turchetto, Lucia ; Radrizzani, Marina ; Zuber, Michel ; Windecker, Stephan ; Moschovitis, Aris ; Bühler, Ines ; Kozerke, Sebastian ; Erne, Paul ; Lüscher, Thomas F. ; Corti, Roberto. / The Effect of Bone Marrow Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction : Twelve Months CMR and Long-Term Clinical Results. In: Circulation Research. 2016.
@article{a2143dddcd6e474cbb709ab35b89cc50,
title = "The Effect of Bone Marrow Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction: Twelve Months CMR and Long-Term Clinical Results",
abstract = "RATIONALE:: Intracoronary delivery of autologous bone marrow derived mononuclear cells (BM-MNC) may improve remodeling of the left ventricle (LV) after acute myocardial infarction (AMI). OBJECTIVE:: To demonstrate long-term efficacy of BM-MNC treatment after AMI. METHODS AND RESULTS:: In a multi-center study, we randomized 200 patients with large AMI in a 1:1:1 pattern into an open-labeled control and two BM-MNC treatment groups. In the BM-MNC groups cells were either administered 5-7 days („early') or 3-4 weeks („late') after AMI. Cardiac magnetic resonance imaging (CMR) was performed at baseline and after 12 months. The current analysis investigates the change from baseline to 12 months in global LV ejection fraction (LVEF), LV-volumes, scar size and NT-proBNP values comparing the two treatment groups with control in a linear regression model. Besides the complete case analysis, multiple imputation analysis was performed to address for missing data. Furthermore the long-term clinical event rate was computed.The absolute change in LVEF from baseline to 12 months was -1.9±9.8 {\%} for control (mean±SD), -0.9±10.5 {\%} for the early and -0.7±10.1 {\%} for the late treatment group. The difference between the groups was not significant, both for complete case analysis and multiple imputation analysis.A combined clinical endpoint occurred equally in all groups. Overall 1-year mortality was low (2.25{\%}). CONCLUSIONS:: Among patients with AMI and LV dysfunction, treatment with BM-MNC either 5-7 days or 3-4 weeks after AMI, did not improve LV-function at 12 months, compared to control. The results are limited by an important drop out rate. CLINICAL TRIAL REGISTRATION INFORMATION:: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00355186",
author = "Daniel S{\"u}rder and Robert Manka and Tiziano Moccetti and {Lo Cicero}, Viviana and Emmert, {Maximilian Y.} and Catherine Klersy and Sabrina Soncin and Lucia Turchetto and Marina Radrizzani and Michel Zuber and Stephan Windecker and Aris Moschovitis and Ines B{\"u}hler and Sebastian Kozerke and Paul Erne and L{\"u}scher, {Thomas F.} and Roberto Corti",
year = "2016",
month = "6",
day = "10",
doi = "10.1161/CIRCRESAHA.116.308639",
language = "English",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - The Effect of Bone Marrow Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction

T2 - Twelve Months CMR and Long-Term Clinical Results

AU - Sürder, Daniel

AU - Manka, Robert

AU - Moccetti, Tiziano

AU - Lo Cicero, Viviana

AU - Emmert, Maximilian Y.

AU - Klersy, Catherine

AU - Soncin, Sabrina

AU - Turchetto, Lucia

AU - Radrizzani, Marina

AU - Zuber, Michel

AU - Windecker, Stephan

AU - Moschovitis, Aris

AU - Bühler, Ines

AU - Kozerke, Sebastian

AU - Erne, Paul

AU - Lüscher, Thomas F.

AU - Corti, Roberto

PY - 2016/6/10

Y1 - 2016/6/10

N2 - RATIONALE:: Intracoronary delivery of autologous bone marrow derived mononuclear cells (BM-MNC) may improve remodeling of the left ventricle (LV) after acute myocardial infarction (AMI). OBJECTIVE:: To demonstrate long-term efficacy of BM-MNC treatment after AMI. METHODS AND RESULTS:: In a multi-center study, we randomized 200 patients with large AMI in a 1:1:1 pattern into an open-labeled control and two BM-MNC treatment groups. In the BM-MNC groups cells were either administered 5-7 days („early') or 3-4 weeks („late') after AMI. Cardiac magnetic resonance imaging (CMR) was performed at baseline and after 12 months. The current analysis investigates the change from baseline to 12 months in global LV ejection fraction (LVEF), LV-volumes, scar size and NT-proBNP values comparing the two treatment groups with control in a linear regression model. Besides the complete case analysis, multiple imputation analysis was performed to address for missing data. Furthermore the long-term clinical event rate was computed.The absolute change in LVEF from baseline to 12 months was -1.9±9.8 % for control (mean±SD), -0.9±10.5 % for the early and -0.7±10.1 % for the late treatment group. The difference between the groups was not significant, both for complete case analysis and multiple imputation analysis.A combined clinical endpoint occurred equally in all groups. Overall 1-year mortality was low (2.25%). CONCLUSIONS:: Among patients with AMI and LV dysfunction, treatment with BM-MNC either 5-7 days or 3-4 weeks after AMI, did not improve LV-function at 12 months, compared to control. The results are limited by an important drop out rate. CLINICAL TRIAL REGISTRATION INFORMATION:: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00355186

AB - RATIONALE:: Intracoronary delivery of autologous bone marrow derived mononuclear cells (BM-MNC) may improve remodeling of the left ventricle (LV) after acute myocardial infarction (AMI). OBJECTIVE:: To demonstrate long-term efficacy of BM-MNC treatment after AMI. METHODS AND RESULTS:: In a multi-center study, we randomized 200 patients with large AMI in a 1:1:1 pattern into an open-labeled control and two BM-MNC treatment groups. In the BM-MNC groups cells were either administered 5-7 days („early') or 3-4 weeks („late') after AMI. Cardiac magnetic resonance imaging (CMR) was performed at baseline and after 12 months. The current analysis investigates the change from baseline to 12 months in global LV ejection fraction (LVEF), LV-volumes, scar size and NT-proBNP values comparing the two treatment groups with control in a linear regression model. Besides the complete case analysis, multiple imputation analysis was performed to address for missing data. Furthermore the long-term clinical event rate was computed.The absolute change in LVEF from baseline to 12 months was -1.9±9.8 % for control (mean±SD), -0.9±10.5 % for the early and -0.7±10.1 % for the late treatment group. The difference between the groups was not significant, both for complete case analysis and multiple imputation analysis.A combined clinical endpoint occurred equally in all groups. Overall 1-year mortality was low (2.25%). CONCLUSIONS:: Among patients with AMI and LV dysfunction, treatment with BM-MNC either 5-7 days or 3-4 weeks after AMI, did not improve LV-function at 12 months, compared to control. The results are limited by an important drop out rate. CLINICAL TRIAL REGISTRATION INFORMATION:: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00355186

UR - http://www.scopus.com/inward/record.url?scp=84978043708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978043708&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.116.308639

DO - 10.1161/CIRCRESAHA.116.308639

M3 - Article

AN - SCOPUS:84978043708

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

ER -